Making cancer clinical trials more relevant

When a new cancer drug improves survival in a clinical trial, it too often remains unclear whether the drug will be effective in clinical practice, asserts a provocative commentary (co-authored by an...

Shortcut clinical trials may be misleading oncologists

Among 55 cancer drugs recently approved on the basis of a surrogate endpoint, less than one-fifth have been shown to improve survival in follow-up clinical trials. Fully two-thirds of new cancer...